Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant
- Issue: Vol 56, No 6 (2011)
- Pages: 28-32
- Section: Articles
- Submitted: 09.06.2023
- Published: 15.12.2011
- URL: https://virusjour.crie.ru/jour/article/view/12113
- ID: 12113
Cite item
Full Text
Abstract
Addition of chitosan to inactivated trivalent polio vaccine or inactivated preparations of attenuated poliomyelitis viruses (Sabin strains) significantly increases immunogenicity of these inactivated poliomyelitis virus preparations. High neutralizing antibody titers are detected after two immunizations of mice and a single immunization of rats, as well as when the antigen dose was reduced by 4 times. Addition of chitosan as an adjuvant significantly induces cellular immunity.
Keywords
References
- Ахматова Н. К., Егорова Н. Б., Курбатова Е. А. и др. Влияние хитозана на иммунофенотип и функциональную активность мононуклеарных лейкоцитов мышей при иммунизации инактивированной противогриппозной вакциной // Журн. микробиол. - 2008. - № 6. - С. 31-35.
- Aguilar J., Rodriguez Е. Vaccine adjuvants revisited // Vaccine. - 2007. - Vol. 25. - P. 3752-3762.
- Atmar R., Keitel W., Patel S. et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations // Clin. Infect. Dis. - 2006. - Vol. 43. - P. 1135-1147.
- Banzhoff A., Gasparini R., Laghi-Pasini F. et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults // PLoS One. - 2009. - Vol. 4. - P. e4384.
- Ghendon Y., Markushin S., Vasiliev Y. et al. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally // J. Med. Virol. - 2009. - Vol. 81. - P. 494-506.
- Ghendon Y., Markushin S., Akopova I. et al. Chitosan as an adjuvant for poliovaccine // J. Med. Virol. - 2011. - Vol. 83. - P. 847-852.
- Gupta R., Siber G. Adjuvants for human vaccines - current status, problems and future prospects // Vaccine. - 1995. - Vol. 13. - P. 1263-1276.
- Ilium L. Chitosan and its use as a pharmaceutical excipient // Pharm. Res. - 1998. - Vol. 15. - P. 1326-1331.
- Ilium L., Jabbal-Gill I., Hinchcliffe M. et al. Chitosan as a novel nasaldelivery system for vaccines // Adv. Drug Deliv. Res. - 2001. - Vol. 51. - P. 81-96.
- Ivanov A., Dragunsky E., Chumakov K. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice // J. Infect. Dis. - 2006. - Vol. 193. - P. 598-600.
- Leroux-Roels I., Bernhard R., Gerard P. et al. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5Nl pandemic influenza vaccine // PLoS One. - 2008. - Vol. 3. - P. e1665.
- Singla A., Chawla M. Chitosan: some pharmaceutical and biological aspects an update // J. Pharm. Pharmacol. - 2011. - Vol. 53. - P. 1047-1067.
- WHO. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, November 2009 // Wkly Epidemiol. Rec. - 2010. - Vol. 85. - P. 1-11.
- WHO. Global detection of wild and vaccine-derived polioviruses, January 2008-June 2009 // Wkly Epidemiol. Rec. - 2009. - Vol. 84. - P. 366-371.
- WHO. Global eradication of poliomyelitis by the year 2000. Geneva: WHO, 1988 (World health assembly resolution WHA41.28).
- WHO. Polio laboratory manual, 4th edition // WHO/IVB/04.10, 2004.
- WHO. Progress towards interrupting wild poliovirus transmission worldwide, 2008 // Wkly Epidemiol. Rec. - 2009. - Vol. 84. - P. 110-116.
- WHO. Recommendations for the production and control of poliomyelitis vaccine (inactivated) // WHO Techn. Rep. Series. - 2002. - № 910, annex 2.
- Yang C., Shi H., Zhou J. et al. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus // Vaccine. - 2009. - Vol. 27. - P. 6558-6563.